We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
-8.53%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.79B
AUM Growth
-$211M
Cap. Flow
+$11.5M
Cap. Flow %
0.64%
Top 10 Hldgs %
29.44%
Holding
145
New
10
Increased
40
Reduced
13
Closed
6

Top Buys

Rank Stock Value
1
COLL icon
Collegium Pharmaceutical
COLL
+$14.5M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$9.75M
3
EPIX
ESSA Pharma
EPIX
+$8.87M
4
XLRN
Acceleron Pharma
XLRN
+$8.72M
5
PEGI
Pattern Energy Group Inc. Class A
PEGI
+$7.95M

Top Sells

Rank Stock Value
1
SCTY
SolarCity Corporation
SCTY
+$31.4M
2
EXR icon
Extra Space Storage
EXR
+$25.2M
3
EOG icon
EOG Resources
EOG
+$10.3M
4
CLDX icon
Celldex Therapeutics
CLDX
+$6.59M
5
CYBR
CyberArk
CYBR
+$4.96M

Sector Composition

Rank Sector Weight
1 Healthcare 28.66%
2 Technology 22.91%
3 Consumer Discretionary 14.14%
4 Industrials 7.47%
5 Utilities 5.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DVAX
76
DELISTED
Dynavax Technologies
DVAX
$4.81M 0.27%
250,000
– –
MCRB icon
77
Seres Therapeutics
MCRB
$46.3M
$4.73M 0.26%
8,910
– –
XNCR icon
78
Xencor
XNCR
$1.59B
$4.62M 0.26%
344,000
– –
TGTX icon
79
TG Therapeutics
TGTX
$8.19B
$4.58M 0.26%
537,600
– –
BPMC
80
DELISTED
Blueprint Medicines
BPMC
$4.45M 0.25%
246,500
– –
ONCE
81
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$4.43M 0.25%
150,000
– –
STML
82
DELISTED
Stemline Therapeutics, Inc.
STML
$3.97M 0.22%
851,400
– –
AGTC
83
DELISTED
Applied Genetic Technologies Corporation
AGTC
$3.9M 0.22%
279,100
– –
TCON
84
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$3.62M 0.2%
2,589
– –
JUNO
85
DELISTED
Juno Therapeutics, Inc.
JUNO
$3.43M 0.19%
90,000
– –
CDTX
86
DELISTED
Cidara Therapeutics
CDTX
$3.35M 0.19%
13,200
– –
EPZM
87
DELISTED
Epizyme, Inc
EPZM
$3.33M 0.19%
+275,000
New +$2.78M
CEMP
88
DELISTED
Cempra, Inc.
CEMP
$3.24M 0.18%
184,900
– –
CHRS icon
89
Coherus Oncology
CHRS
$227M
$3.08M 0.17%
+145,000
New +$2.38M
ATRC icon
90
AtriCure
ATRC
$2.04B
$3.03M 0.17%
180,000
– –
RGEN icon
91
Repligen
RGEN
$8.1B
$2.95M 0.16%
110,000
-92,000
-46% -$2.25M
INCY icon
92
Incyte
INCY
$24.9B
$2.9M 0.16%
+40,000
New +$2.98M
NTUS
93
DELISTED
Natus Medical Inc
NTUS
$2.88M 0.16%
75,000
-73,900
-50% -$2.75M
VRTX icon
94
Vertex Pharmaceuticals
VRTX
$122B
$2.75M 0.15%
34,600
– –
INSM icon
95
Insmed
INSM
$22B
$2.66M 0.15%
210,000
– –
VYGR icon
96
Voyager Therapeutics
VYGR
$189M
$2.62M 0.15%
300,000
+50,000
+20% +$567K
GBT
97
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.62M 0.15%
165,000
– –
IMDZ
98
DELISTED
Immune Design Corp.
IMDZ
$2.34M 0.13%
180,000
– –
LKFT
99
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$2.17M 0.12%
+52,000
New +$2.41M
QURE icon
100
uniQure
QURE
$2.93B
$2.08M 0.12%
174,900
– –
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q1 2016 Portfolio in Review

As of Q1 2016, Eventide Asset Management held 145 positions worth $1.79B, down 11% from $2B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Eventide Asset Management's Q1 2016 filing shows 10 new, 40 increased, 13 reduced and 6 closed positions. Its largest new stake was ESSA Pharma: 135,971 shares worth $7.83M. The largest sale was SolarCity Corporation, an estimated $31.4M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 30% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Eventide Asset Management's largest Q1 2016 buy was ESSA Pharma: 135,971 shares worth $7.83M.
  • Eventide Asset Management added most to Collegium Pharmaceutical in Q1 2016, an estimated $14.5M increase.
  • Eventide Asset Management's biggest Q1 2016 reduction was Extra Space Storage, cutting an estimated $25.2M.
  • Eventide Asset Management fully exited SolarCity Corporation in Q1 2016, selling an estimated $31.4M.
  • Eventide Asset Management's ten largest holdings make up 29% of its $1.79B portfolio in Q1 2016.
  • Eventide Asset Management opened 10 new positions and closed 6 in Q1 2016.
  • Eventide Asset Management's portfolio value fell 11% quarter-over-quarter to $1.79B.

Based on Eventide Asset Management's 13F filing for Q1 2016, filed 16 May 2016.